Rachel Humphrey Biography and Net Worth

Director of Pyxis Oncology

Dr. Humphrey is a medical oncologist with over 25 years of experience in the pharmaceutical industry. Currently she serves as President and Founding CEO of Normunity, a Boston-based biotech focused on immune-oncology. She was Founder and Acting CEO of NorthBridge Therapeutics. Over the course of her career, she’s served as Chief Medical Officer in multiple biotechnology companies, including Black Diamond Therapeutics, CytomX therapeutics and Mirati Therapeutics. She’s also held numerous senior leadership roles in large pharmaceutical companies including SVP and Head of Immuno-Oncology at AstraZeneca, and VP, Clinical Development and Immuno-oncology at Bristol-Myers Squibb (BMS) where she supervised the development of ipilimumab (Yervoy) from early development to post-launch and founded/chaired the first Immuno-oncology working group. She currents serves on the board of directors of Sporos Biosciences and Asylia Therapeutics, and previously served on the Board of Directors of Xilio and CytomX Therapeutics, respectively. Dr. Humphrey holds an M.D. from Case Western Reserve University and a B.A. from Harvard University. She received her training in internal medicine at The Johns Hopkins Hospital and started her career as an oncology fellow and staff physician at the National Cancer Institute in Bethesda, MD.

What is Rachel Humphrey's net worth?: The estimated net worth of Rachel Humphrey is at least $236.61 thousand as of April 21st, 2025. Dr. Humphrey owns 81,309 shares of Pyxis Oncology stock worth more than $236,609 as of July 28th. This net worth approximation does not reflect any other assets that Dr. Humphrey may own. Learn More about Rachel Humphrey's net worth.
How do I contact Rachel Humphrey?: The corporate mailing address for Dr. Humphrey and other Pyxis Oncology executives is , , . Pyxis Oncology can also be reached via phone at 617-221-9059 and via email at [email protected]. Learn More on Rachel Humphrey's contact information.
Has Rachel Humphrey been buying or selling shares of Pyxis Oncology?: Rachel Humphrey has not been actively trading shares of Pyxis Oncology in the last ninety days. Most recently, Rachel Humphrey sold 13,896 shares of the business's stock in a transaction on Monday, April 21st. The shares were sold at an average price of $1.03, for a transaction totalling $14,312.88. Following the completion of the sale, the director now directly owns 81,309 shares of the company's stock, valued at $83,748.27. Learn More on Rachel Humphrey's trading history.
Who are Pyxis Oncology's active insiders?: Pyxis Oncology's insider roster includes Thomas Civik (Director), Darren Cline (Director), and Rachel Humphrey (Director). Learn More on Pyxis Oncology's active insiders.

Rachel Humphrey Insider Trading History at Pyxis Oncology

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/21/2025	Sell	13,896	$1.03	$14,312.88	81,309
4/17/2025	Sell	200	$0.97	$194.00	95,205
4/14/2025	Sell	1,400	$0.97	$1,358.00	95,405

Rachel Humphrey Buying and Selling Activity at Pyxis Oncology

Pyxis Oncology Company Overview

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.

Today's Range

Now: $2.82

$2.74

$2.90

50 Day Range

MA: $2.18

$1.63

$3.07

2 Week Range

Now: $2.82

$0.97

$5.55

Volume

131,195 shs

Average Volume

757,244 shs

Market Capitalization

$178.65 million

P/E Ratio

N/A

Dividend Yield